BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Anderson LJ, Wonke B, Prescott E, Holden S, Malcolm Walker J, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. The Lancet 2002;360:516-20. [DOI: 10.1016/s0140-6736(02)09740-4] [Cited by in Crossref: 291] [Cited by in F6Publishing: 70] [Article Influence: 15.3] [Reference Citation Analysis]
Number Citing Articles
1 He X, Hahn P, Iacovelli J, Wong R, King C, Bhisitkul R, Massaro-Giordano M, Dunaief JL. Iron homeostasis and toxicity in retinal degeneration. Prog Retin Eye Res 2007;26:649-73. [PMID: 17921041 DOI: 10.1016/j.preteyeres.2007.07.004] [Cited by in Crossref: 132] [Cited by in F6Publishing: 119] [Article Influence: 9.4] [Reference Citation Analysis]
2 Musumeci M, Maccari S, Sestili P, Massimi A, Corritore E, Marano G, Catalano L. The C57BL/6 genetic background confers cardioprotection in iron-overloaded mice. Blood Transfus 2013;11:88-93. [PMID: 22790263 DOI: 10.2450/2012.0176-11] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
3 Kwiatkowski JL. Management of transfusional iron overload - differential properties and efficacy of iron chelating agents. J Blood Med 2011;2:135-49. [PMID: 22287873 DOI: 10.2147/JBM.S13065] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
4 Gattermann N. The treatment of secondary hemochromatosis. Dtsch Arztebl Int 2009;106:499-504, I. [PMID: 19727383 DOI: 10.3238/arztebl.2009.0499] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 0.3] [Reference Citation Analysis]
5 Bidhult S, Xanthis CG, Liljekvist LL, Greil G, Nagel E, Aletras AH, Heiberg E, Hedström E. Validation of a new T2* algorithm and its uncertainty value for cardiac and liver iron load determination from MRI magnitude images. Magn Reson Med 2016;75:1717-29. [PMID: 26010550 DOI: 10.1002/mrm.25767] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 Mavrogeni S. Evaluation of myocardial iron overload using magnetic resonance imaging. Blood Transfus 2009;7:183-7. [PMID: 19657481 DOI: 10.2450/2008.0063-08] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 Masera N, Tavecchia L, Longoni DV, Maglia O, Biondi A, Masera G. Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination. Blood Transfus 2011;9:462-5. [PMID: 21839013 DOI: 10.2450/2011.0098-10] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
8 Wood JC, Otto-Duessel M, Aguilar M, Nick H, Nelson MD, Coates TD, Pollack H, Moats R. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation. 2005;112:535-543. [PMID: 16027257 DOI: 10.1161/circulationaha.104.504415] [Cited by in Crossref: 164] [Cited by in F6Publishing: 70] [Article Influence: 10.3] [Reference Citation Analysis]
9 Vlachos A, Muir E. How I treat Diamond-Blackfan anemia. Blood 2010;116:3715-23. [PMID: 20651069 DOI: 10.1182/blood-2010-02-251090] [Cited by in Crossref: 118] [Cited by in F6Publishing: 86] [Article Influence: 10.7] [Reference Citation Analysis]
10 Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:11. [PMID: 20492708 DOI: 10.1186/1750-1172-5-11] [Cited by in Crossref: 501] [Cited by in F6Publishing: 360] [Article Influence: 45.5] [Reference Citation Analysis]
11 Ghugre NR, Enriquez CM, Coates TD, Nelson MD Jr, Wood JC. Improved R2* measurements in myocardial iron overload. J Magn Reson Imaging 2006;23:9-16. [PMID: 16329085 DOI: 10.1002/jmri.20467] [Cited by in Crossref: 116] [Cited by in F6Publishing: 108] [Article Influence: 7.7] [Reference Citation Analysis]
12 Tubman VN, Fung EB, Vogiatzi M, Thompson AA, Rogers ZR, Neufeld EJ, Kwiatkowski JL; Thalassemia Clinical Research Network. Guidelines for the Standard Monitoring of Patients With Thalassemia: Report of the Thalassemia Longitudinal Cohort. J Pediatr Hematol Oncol 2015;37:e162-9. [PMID: 26201037 DOI: 10.1097/MPH.0000000000000307] [Cited by in Crossref: 29] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
13 He T, Kirk P, Firmin DN, Lam WM, Chu WC, Au WY, Chan GC, Tan RS, Ng I, Biceroglu S, Aydinok Y, Fogel MA, Cohen AR, Pennell DJ. Multi-center transferability of a breath-hold T2 technique for myocardial iron assessment. J Cardiovasc Magn Reson 2008;10:11. [PMID: 18291040 DOI: 10.1186/1532-429X-10-11] [Cited by in Crossref: 32] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
14 Wood JC, Aguilar M, Otto-Duessel M, Nick H, Nelson MD, Moats R. Influence of iron chelation on R1 and R2 calibration curves in gerbil liver and heart. Magn Reson Med 2008;60:82-9. [PMID: 18581418 DOI: 10.1002/mrm.21660] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
15 Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006;107:3436-41. [PMID: 16627763 DOI: 10.1182/blood-2006-02-002394] [Cited by in Crossref: 193] [Cited by in F6Publishing: 159] [Article Influence: 12.9] [Reference Citation Analysis]
16 Badeli H, Baghersalimi A, Eslami S, Saadat F, Rad AH, Basavand R, Papkiadeh SR, Darbandi B, Kooti W, Peluso I. Early Kidney Damage Markers after Deferasirox Treatment in Patients with Thalassemia Major: A Case-Control Study. Oxid Med Cell Longev 2019;2019:5461617. [PMID: 31178966 DOI: 10.1155/2019/5461617] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
17 Ward RJ, Dexter DT, Martin-Bastida A, Crichton RR. Is Chelation Therapy a Potential Treatment for Parkinson's Disease? Int J Mol Sci 2021;22:3338. [PMID: 33805195 DOI: 10.3390/ijms22073338] [Reference Citation Analysis]
18 Baksi AJ, Pennell DJ. Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major. Front Pharmacol 2014;5:217. [PMID: 25295007 DOI: 10.3389/fphar.2014.00217] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
19 Cao A, Moi P, Galanello R. Recent advances in β-thalassemias. Pediatr Rep 2011;3:e17. [PMID: 21772954 DOI: 10.4081/pr.2011.e17] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
20 Cianciulli P. Iron chelation therapy in thalassemia syndromes. Mediterr J Hematol Infect Dis 2009;1:e2009034. [PMID: 21415999 DOI: 10.4084/MJHID.2009.034] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Ghugre NR, Enriquez CM, Gonzalez I, Nelson MD, Coates TD, Wood JC. MRI detects myocardial iron in the human heart. Magn Reson Med. 2006;56:681-686. [PMID: 16888797 DOI: 10.1002/mrm.20981] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 5.9] [Reference Citation Analysis]
22 Savulescu J. Thalassaemia major: the murky story of deferiprone. BMJ. 2004;328:358-359. [PMID: 14962851 DOI: 10.1136/bmj.328.7436.358] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
23 Kalanaky S, Hafizi M, Safari S, Mousavizadeh K, Kabiri M, Farsinejad A, Fakharzadeh S, Nazaran MH. TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo. Int J Hematol 2016;103:274-82. [PMID: 26830968 DOI: 10.1007/s12185-015-1932-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
24 Grady RW, Galanello R, Randolph RE, Kleinert DA, Dessi C, Giardina PJ. Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine. Haematologica 2013;98:129-35. [PMID: 22875626 DOI: 10.3324/haematol.2012.070607] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
25 Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008;10:12. [PMID: 18298856 DOI: 10.1186/1532-429X-10-12] [Cited by in Crossref: 136] [Cited by in F6Publishing: 57] [Article Influence: 10.5] [Reference Citation Analysis]
26 Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood 2008;112:2973-8. [PMID: 18650452 DOI: 10.1182/blood-2008-04-148767] [Cited by in Crossref: 131] [Cited by in F6Publishing: 126] [Article Influence: 10.1] [Reference Citation Analysis]
27 Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42. [PMID: 18817553 DOI: 10.1186/1532-429x-10-42] [Cited by in Crossref: 307] [Cited by in F6Publishing: 131] [Article Influence: 23.6] [Reference Citation Analysis]
28 Dubey AP, Parakh A, Dublish S. Current trends in the management of beta thalassemia. Indian J Pediatr 2008;75:739-43. [PMID: 18716746 DOI: 10.1007/s12098-008-0140-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
29 Remacha A, Sanz C, Contreras E, De Heredia CD, Grifols JR, Lozano M, Nuñez GM, Salinas R, Corral M, Villegas A; Spanish Society of Blood Transfusion., Spanish Society of Haematology and Haemotherapy. Guidelines on haemovigilance of post-transfusional iron overload. Blood Transfus 2013;11:128-39. [PMID: 22790272 DOI: 10.2450/2012.0114-11] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
30 Crichton RR, Ward RJ, Hider RC. The Efficacy of Iron Chelators for Removing Iron from Specific Brain Regions and the Pituitary-Ironing out the Brain. Pharmaceuticals (Basel) 2019;12:E138. [PMID: 31533229 DOI: 10.3390/ph12030138] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
31 Alpendurada F, Smith GC, Carpenter JP, Nair SV, Tanner MA, Banya W, Dessi C, Galanello R, Walker JM, Pennell DJ. Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major. J Cardiovasc Magn Reson 2012;14:8. [PMID: 22277065 DOI: 10.1186/1532-429X-14-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
32 Barton JC. Chelation therapy for iron overload. Curr Gastroenterol Rep 2007;9:74-82. [PMID: 17335681 DOI: 10.1007/s11894-008-0024-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
33 Aessopos A, Berdoukas V, Tsironi M. The heart in transfusion dependent homozygous thalassaemia today--prediction, prevention and management. Eur J Haematol 2008;80:93-106. [PMID: 18081719 DOI: 10.1111/j.1600-0609.2007.01018.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
34 Berdoukas V, Wood J. In search of the optimal iron chelation therapy for patients with thalassemia major. Haematologica 2011;96:5-8. [PMID: 21193427 DOI: 10.3324/haematol.2010.034397] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
35 Wood JC. Cardiac iron across different transfusion-dependent diseases. Blood Rev 2008;22 Suppl 2:S14-21. [PMID: 19059052 DOI: 10.1016/S0268-960X(08)70004-3] [Cited by in Crossref: 88] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
36 Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008;10:12. [PMID: 18298856 DOI: 10.1186/1532429x1012] [Reference Citation Analysis]
37 Sirlin CB, Reeder SB. Magnetic resonance imaging quantification of liver iron. Magn Reson Imaging Clin N Am. 2010;18:359-381, ix. [PMID: 21094445 DOI: 10.1016/j.mric.2010.08.014] [Cited by in Crossref: 107] [Cited by in F6Publishing: 92] [Article Influence: 10.7] [Reference Citation Analysis]
38 Xu J, Jia Z, Knutson MD, Leeuwenburgh C. Impaired iron status in aging research. Int J Mol Sci 2012;13:2368-86. [PMID: 22408459 DOI: 10.3390/ijms13022368] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
39 Luangasanatip N, Chaiyakunapruk N, Upakdee N, Wong P. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study. Clin Drug Investig. 2011;31:493-505. [PMID: 21627338 DOI: 10.2165/11587120-000000000-00000] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
40 Wood JC. History and current impact of cardiac magnetic resonance imaging on the management of iron overload. Circulation 2009;120:1937-9. [PMID: 19884464 DOI: 10.1161/CIRCULATIONAHA.109.907196] [Cited by in Crossref: 52] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
41 Jamuar SS, Lai AH. Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia. Ther Adv Hematol 2012;3:299-307. [PMID: 23616917 DOI: 10.1177/2040620712450252] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
42 Tziomalos K, Perifanis V. Liver iron content determination by magnetic resonance imaging. World J Gastroenterol. 2010;16:1587-1597. [PMID: 20355237 DOI: 10.3748/wjg.v16.i13.1587] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
43 Barton JC. Optimal management strategies for chronic iron overload. Drugs 2007;67:685-700. [PMID: 17385941 DOI: 10.2165/00003495-200767050-00004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
44 Mitchell FM, Prasad SK, Greil GF, Drivas P, Vassiliou VS, Raphael CE. Cardiovascular magnetic resonance: Diagnostic utility and specific considerations in the pediatric population. World J Clin Pediatr 2016;5:1-15. [PMID: 26862497 DOI: 10.5409/wjcp.v5.i1.1] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.2] [Reference Citation Analysis]
45 Vassiliadis T, Garipidou V, Perifanis V, Tziomalos K, Giouleme O, Patsiaoura K, Avramidis M, Nikolaidis N, Vakalopoulou S, Tsitouridis I, Antoniadis A, Semertzidis P, Kioumi A, Premetis E, Eugenidis N. A case of successful management with splenectomy of intractable ascites due to congenital dyserythropoietic anemia type II-induced cirrhosis. World J Gastroenterol 2006;12:818-21. [PMID: 16521204 DOI: 10.3748/wjg.v12.i5.818] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
46 Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112:2973-2978. [PMID: 18650452 DOI: 10.1182/blood200804148767] [Reference Citation Analysis]
47 Kumar A, Patton DJ, Friedrich MG. The emerging clinical role of cardiovascular magnetic resonance imaging. Can J Cardiol 2010;26:313-22. [PMID: 20548977 DOI: 10.1016/s0828-282x(10)70396-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
48 Kalisz K, Rajiah P. Impact of cardiac magnetic resonance imaging in non-ischemic cardiomyopathies. World J Cardiol 2016;8:132-45. [PMID: 26981210 DOI: 10.4330/wjc.v8.i2.132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
49 Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD. An update on iron chelation therapy. Blood Transfus 2012;10:411-22. [PMID: 22790257 DOI: 10.2450/2012.0008-12] [Cited by in F6Publishing: 54] [Reference Citation Analysis]
50 Thuret I, Pondarré C, Loundou A, Steschenko D, Girot R, Bachir D, Rose C, Barlogis V, Donadieu J, de Montalembert M, Hagege I, Pegourie B, Berger C, Micheau M, Bernaudin F, Leblanc T, Lutz L, Galactéros F, Siméoni MC, Badens C. Complications and treatment of patients with β-thalassemia in France: results of the National Registry. Haematologica 2010;95:724-9. [PMID: 20007138 DOI: 10.3324/haematol.2009.018051] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
51 Kontoghiorghe CN, Kontoghiorghes GJ. New developments and controversies in iron metabolism and iron chelation therapy. World J Methodol 2016;6:1-19. [PMID: 27019793 DOI: 10.5662/wjm.v6.i1.1] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
52 Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42. [PMID: 18817553 DOI: 10.1186/1532429x1042] [Reference Citation Analysis]
53 Wood JC, Otto-Duessel M, Gonzalez I, Aguilar MI, Shimada H, Nick H, Nelson M, Moats R. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res. 2006;148:272-280. [PMID: 17145573 DOI: 10.1016/j.trsl.2006.05.005] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
54 Berdoukas V, Farmaki K, Carson S, Wood J, Coates T. Treating thalassemia major-related iron overload: the role of deferiprone. J Blood Med 2012;3:119-29. [PMID: 23112580 DOI: 10.2147/JBM.S27400] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
55 Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 2003;26:553-84. [PMID: 12825969 DOI: 10.2165/00002018-200326080-00003] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 4.1] [Reference Citation Analysis]
56 Musallam KM, Taher AT. Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major. Haematologica 2011;96:e5-6; author reply e7-8. [PMID: 21282714 DOI: 10.3324/haematol.2010.036061] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
57 Yang G, Liu R, Peng P, Long L, Zhang X, Yang W, Tan S, Pan H, Long X, He T, Anderson L, Lai Y. How early can myocardial iron overload occur in beta thalassemia major? PLoS One 2014;9:e85379. [PMID: 24465548 DOI: 10.1371/journal.pone.0085379] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
58 Al-Mallah MH, Shareef MN. The role of cardiac magnetic resonance imaging in the assessment of non-ischemic cardiomyopathy. Heart Fail Rev. 2011;16:369-380. [PMID: 21170585 DOI: 10.1007/s10741-010-9221-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
59 Olivieri NF, Brittenham GM. Management of the thalassemias. Cold Spring Harb Perspect Med 2013;3:a011767. [PMID: 23732853 DOI: 10.1101/cshperspect.a011767] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
60 Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica. 2012;97:842-848. [PMID: 22271905 DOI: 10.3324/haematol.2011.049957] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 8.8] [Reference Citation Analysis]
61 Leiner T, Bogaert J, Friedrich MG, Mohiaddin R, Muthurangu V, Myerson S, Powell AJ, Raman SV, Pennell DJ. SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2020;22:76. [PMID: 33161900 DOI: 10.1186/s12968-020-00682-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 20.0] [Reference Citation Analysis]
62 Virtanen JM, Remes KJ, Itälä-Remes MA, Saunavaara JP, Komu ME, Partanen AM, Parkkola RK. The relationship between cardiac and liver iron evaluated by MR imaging in haematological malignancies and chronic liver disease. Blood Cancer J 2012;2:e49. [PMID: 22829233 DOI: 10.1038/bcj.2011.48] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
63 Saliba AN, Harb AR, Taher AT. Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. J Blood Med 2015;6:197-209. [PMID: 26124688 DOI: 10.2147/JBM.S72463] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
64 Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, Putti MC, Lippi A, Romeo MA, Bisconte MG. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011;96:41-47. [PMID: 20884710 DOI: 10.3324/haematol.2009.019042] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 8.1] [Reference Citation Analysis]
65 Westwood MA, Firmin DN, Gildo M, Renzo G, Stathis G, Markissia K, Vasili B, Pennell DJ. Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. Int J Cardiovasc Imaging 2005;21:531-8. [PMID: 16175443 DOI: 10.1007/s10554-005-0651-2] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 5.1] [Reference Citation Analysis]
66 Ansari S, Azarkeivan A, Miri-Aliabad G, Yousefian S, Rostami T. Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior. Caspian J Intern Med 2017;8:159-64. [PMID: 28932366 DOI: 10.22088/cjim.8.3.159] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
67 Lota AS, Gatehouse PD, Mohiaddin RH. T2 mapping and T2* imaging in heart failure. Heart Fail Rev 2017;22:431-40. [PMID: 28497231 DOI: 10.1007/s10741-017-9616-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
68 Caro J, Huybrechts KF, Green TC. Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review. BMC Blood Disord 2002;2:4. [PMID: 12441006 DOI: 10.1186/1471-2326-2-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
69 Pennell DJ, Carpenter JP, Roughton M, Cabantchik Z. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. J Cardiovasc Magn Reson. 2011;13:45. [PMID: 21910880 DOI: 10.1186/1532-429x-13-45] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
70 Jensen PD. Iron overload in patients with myelodysplastic syndromes. Curr Hematol Malig Rep 2007;2:13-21. [PMID: 20425384 DOI: 10.1007/s11899-007-0003-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]